Skip to content
Pharma Observatory a Scientist.com platform

Organization (Other)

Sanofi Pasteur, a Sanofi Company

ClinicalTrials.gov lists Sanofi Pasteur, a Sanofi Company as lead sponsor of 374 trials. It has 208 active development programs and 91 approved assets.

Other
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

35 0 1998 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 1 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 3 in 2026 and about 8 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

This page covers Sanofi Pasteur, a Sanofi Company: 374 lead-sponsored trials and 0 legal-entity registrations.

Get the Sanofi Pasteur, a Sanofi Company report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (65)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Influenza, Human 135
Whooping Cough 64
Clostridium Infections 62
Diphtheria 58
Meningococcal Infections 56

Trials by start year as sponsor or collaborator (27)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 1
2025 7
2024 21
2023 9
2022 16
2021 19
2020 20
2019 17
2018 19
2017 12

Prediction, not a registry value: median of 36 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 12 months across 364 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (208)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
Yellow Fever Vaccine Yellow Fever Phase 3 6
Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine Meningococcal Infections Phase 3 12
PCV21 Pneumococcal Infections Phase 3 1
20vPCV Pneumococcal Infections Phase 3 1
PCV21 Streptococcal Infections Phase 3 1

Approved assets (91)

Shown in this order: max phase first.

Approved assets
Drug Trials
Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine 11
Influenza Virus Vaccine 10
Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate 9
MenACYW conjugate vaccine 8
Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate 4

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
53% hit target (n=97) 35% on time (n=107)

Journals published in (88)

Shown in this order: most published in first.

Journals published in
Journal Publications
Vaccine 62
Human vaccines & immunotherapeutics 34
The Pediatric infectious disease journal 27
The Journal of infectious diseases 19
The New England journal of medicine 11

Organization relationships (4)

Shown in this order: most evidence first.

Organization relationships
Related organization Relationship Evidence
International Maternal Pediatric Adolescent AIDS Clinical Trials Group Co sponsors trial with 1
Scott Halperin Co sponsors trial with 1
Institut Pasteur of Cote d'Ivoire Co sponsors trial with 1
Clinique Antilles-Guyane Co sponsors trial with 1

Latest dated events (431)

Shown in this order: newest first.

Latest dated events
Date Event Source
2026-04-20 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2025-12-05 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2025-10-23 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2025-07-03 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2025-02-28 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Biomarker capability evidence (143)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ALB Trial sponsor Primary endpoint in a Phase 3 trial
ALB Trial sponsor Primary endpoint in a Phase 3 trial
ARIH1 Trial sponsor Named in trial inclusion criteria
CD4 Trial sponsor Named in trial inclusion criteria
CD4 Trial sponsor Named in trial inclusion criteria

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.